Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, has launched propofol injectable emulsion USP 1%, in two single-dose, single-patient vial presentations of 20 mL and 100 mL. A 50 mL single-dose, single-patient vial presentation will be released shortly.

According to IMS, for the 12 months ending September 2013, the US market for Propofol approximated $230 million.

"Sagent has a strong commitment to responding to our customers' needs by providing an extensive portfolio of injectable pharmaceutical products. One challenge many customers face is maintaining adequate supply of certain key products that are only available from a limited number of sources. Sagent has again fulfilled its commitment to our customers by becoming an alternative supplier of Propofol," said Jeffrey M Yordon, chief executive officer and chairman of the Board of Sagent.

Sagent Pharmaceuticals, Inc. is focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.